Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats

Diabetologia

Volumn 56, Issue 8, 2013, Pages 1826-1834

  Tennagels, N ^a   Welte, S ^a   Hofmann, M ^a   Brenk, P ^a   Schmidt, R ^a   Werner, U ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Akt; Asp B10 insulin; Human insulin; IGF 1 receptor; Insulin glargine; Insulin receptor; Receptor phosphorylation

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN ASPART B10; INSULIN GLARGINE; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY FAT; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEART; INSULIN BLOOD LEVEL; LIVER; MALE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD GLUCOSE; HUMANS; INSULIN; INSULIN ASPART; INSULIN, LONG-ACTING; MALE; PHOSPHORYLATION; RATS; RATS, WISTAR; RECEPTOR, INSULIN;

EID: 84879954915     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2923-z     Document Type: Article

References (47)

1. Rossetti P, Porcellati F, Fanelli CG, Perriello G, Torlone E, Bolli GB (2008) Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Arch Physiol Biochem 114:3-10
2. Le Roith D (2007) Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev 23:593-599
3. Hansen BF, Kurtzhals P, Jensen AB, Dejgaard A, Russell-Jones D (2011) Insulin X10 revisited: a super-mitogenic insulin analogue. Diabetologia 54:2226-2231
4. Bahr M, Kolter T, Seipke G, Eckel J (1997) Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32]insulin (HOE 901) in muscle cells. Eur J Pharmacol 320:259-265
5. Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring HU (1998) The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res 30:123-129
6. Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005
7. Sommerfeld MR, Muller G, Tschank G et al (2010) In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One 5:e9540
8. Kuerzel GU, Shukla U, Scholtz HE et al (2003) Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 19:34-40
9. Werner U, Schmidt R, Blair E, Renna SM, Tennagels N (2012) The molecular mechanism of insulin glargine metabolism in vivo. Diabetes 61(suppl 1):A425, Abstract
10. Tennagels N, Werner U (2013) The metabolic and mitogenic properties of basal insulin analogues. Arch Physiol Biochem 119:1-14
11. Bolli GB, Hahn A, Schmidt R et al (2012) Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes mellitus. Diabetes Care 35:2626-2630
12. Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G (2002) Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 21:171-179
13. Ballard FJ, Wallace JC, Francis GL, Read LC, Tomas FM (1996) Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol 28:1085-1087
14. Baus D, Heermeier K, De Hoop M et al (2008) Identification of a novel AS160 splice variant that regulates GLUT4 translocation and glucose-uptake in rat muscle cells. Cell Signal 20:2237-2246
15. Pillai O, Panchagnula R (2001) Insulin therapies - past, present and future. Drug Discov Today 6:1056-1061
16. Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7:85-96
17. Hvid H, Fels JJ, Kirk RK et al (2011) In situ phosphorylation of Akt and ERK1/2 in rat mammary gland, colon, and liver following treatment with human insulin and IGF-1. Toxicol Pathol 39:623-640
18. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A (2002) Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277:39684-39695
19. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586-623
20. Moxham CP, Duronio V, Jacobs S (1989) Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 264:13238-13244
21. Pandini G, Vigneri R, Costantino A et al (1999) Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5:1935-1944
22. Soos MA, Field CE, Siddle K (1993) Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 290(Pt 2):419-426
23. Sandow J (2009) Growth effects of insulin and insulin analogues. Arch Physiol Biochem 115:72-85
24. Eckardt K, May C, Koenen M, Eckel J (2007) IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 50:2534-2543
25. Mayer D, Shukla A, Enzmann H (2008) Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 114:38-44
26. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429-441
27. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2009) Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25:41-49
28. Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, Werner H (2010) Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia 53:2667-2675
29. Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR (2001) Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 86:5838-5847
30. Liefvendahl E, Arnqvist HJ (2008) Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 40:369-374
31. Mussig K, Staiger H, Kantartzis K, Fritsche A, Kanz L, Haring HU (2010) Diabetes, insulin, insulin analogues, and cancer. Dtsch Med Wochenschr 135:924-929, article in German
32. Staiger K, Staiger H, Schweitzer MA et al (2005) Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia 48:1898-1905
33. Staiger K, Hennige AM, Staiger H, Haring HU, Kellerer M (2007) Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 39:65-67
34. Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T (2008) Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Diabetes Res Clin Pract 81:269-277
35. Drejer K (1992) The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8:259-285
36. Sciacca L, Cassarino MF, Genua M et al (2010) Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53:1743-1753
37. Stammberger I, Essermeant L (2012) Insulin glargine: a reevaluation of rodent carcinogenicity findings. Int J Toxicol 31:137-142
38. Nagel JM, Staffa J, Renner-Muller I et al (2010) Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice. Horm Cancer 1:320-330
39. Agouni A, Owen C, Czopek A, Mody N, Delibegovic M (2010) In vivo differential effects of fasting, re-feeding, insulin and insulin stimulation time course on insulin signaling pathway components in peripheral tissues. Biochem Biophys Res Commun 401:104-111
40. Hennige AM, Lehmann R, Weigert C et al (2005) Insulin glulisine: insulin receptor signaling characteristics in vivo. Diabetes 54:361-366
41. Berchtold H, Hilgenfeld R (1999) Binding of phenol to R6 insulin hexamers. Biopolymers 51:165-172
42. Lucidi P, Porcellati F, Rossetti P et al (2012) Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes mellitus. Diabetes Care 35(2):2647-2649
43. Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R (2007) Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab 33:205-212
44. Ikeda H, Shiojima I, Ozasa Y et al (2009) Interaction of myocardial insulin receptor and IGF receptor signaling in exercise-induced cardiac hypertrophy. J Mol Cell Cardiol 47:664-675
45. Lee AV, Taylor ST, Greenall J et al (2003) Rapid induction of IGF-IR signaling in normal and tumor tissue following intravenous injection of IGF-I in mice. Horm Metab Res 35:651-655
46. Walton PE, Gopinath R, Burleigh BD, Etherton TD (1989) Administration of recombinant human insulin-like growth factor I to pigs: determination of circulating half-lives and chromatographic profiles. Horm Res 31:138-142
47. Pierre-Eugene C, Pagesy P, Nguyen TT et al (2012) Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. PLoS One 7:e41992